Akorn (OTCMKTS:AKRXQ) is a specialty generic pharmaceutical company focused on the development, manufacturing and commercialization of high-value injectable, ophthalmic, otic, dermatologic and oncology products. The company’s portfolio also includes sterile injectables, ophthalmic solutions and suspensions, pulmonary inhalations and anti-infective products designed to serve hospital, retail and long-term care markets across the United States.
In addition to its branded generic offerings, Akorn provides contract development and manufacturing services for both sterile and non-sterile dosage forms. Its capabilities encompass formulation development, scale-up, clinical and commercial manufacturing, finished-dose packaging and analytical testing. The company’s services support pharmaceutical sponsors seeking to outsource components of the product lifecycle, including sterile compounding and compliance with U.S. Food and Drug Administration (FDA) standards.
Founded in 1971 and headquartered in Lake Forest, Illinois, Akorn maintained multiple manufacturing and research facilities across the U.S., including sites in Illinois, New York and New Jersey. After facing regulatory and financial challenges, the company underwent a restructuring process in 2020. Its core assets were subsequently acquired by Fresenius Kabi AG, allowing many of its operations and product lines to continue under the Fresenius Kabi portfolio.
AI Generated. May Contain Errors.
Free AKRXQ Stock Alerts